{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:24:52Z","timestamp":1783992292736,"version":"3.55.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.2146\/ajhp160559","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T10:40:11Z","timestamp":1495708811000},"page":"795-810","source":"Crossref","is-referenced-by-count":8,"title":["Considerations and controversies in managing chronic kidney disease: An update"],"prefix":"10.1093","volume":"74","author":[{"given":"Lalita","family":"Prasad-Reddy","sequence":"first","affiliation":[{"name":"Chicago State University, Chicago, IL; and Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Diabetes Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kantorovich","sequence":"additional","affiliation":[{"name":"Chicago State University College of Pharmacy, Chicago, IL; and Advocate Christ Medical Center, Oak Lawn, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103310274500_b1-0740795","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.2014.128","article-title":"Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes","volume":"87","author":"Molitch","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103310274500_b2-0740795","unstructured":"Centers for Disease Control and Prevention. National chronic kidney disease fact sheet, 2014. www.cdc.gov\/diabetes\/pubs\/pdf\/kidney_fact-sheet.pdf (accessed 2015 Aug 1)."},{"issue":"suppl 113","key":"key\n\t\t\t\t2019041103310274500_b3-0740795","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Work Group","year":"2009","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103310274500_b4-0740795","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"suppl 3","key":"key\n\t\t\t\t2019041103310274500_b5-0740795","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"KDOQI, National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b6-0740795","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041103310274500_b7-0740795","first-page":"S1","article-title":"Standards of medical care in diabetes","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019041103310274500_b8-0740795","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b9-0740795","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t2019041103310274500_b10-0740795","first-page":"368","article-title":"Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease","volume":"4","author":"Vos","year":"2011","journal-title":"NDT Plus"},{"key":"key\n\t\t\t\t2019041103310274500_b11-0740795","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b12-0740795","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b13-0740795","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/diaclin.25.3.90","article-title":"Diabetes management issues for patients with chronic kidney disease","volume":"25","author":"Cavanaugh","year":"2007","journal-title":"Clin Diabetes"},{"key":"key\n\t\t\t\t2019041103310274500_b14-0740795","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103310274500_b15-0740795","unstructured":"Food and Drug Administration. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function (April08, 2016). www.fda.gov\/Drugs\/DrugSafety\/ucm493244.htm (accessed 2016 May 14)."},{"key":"key\n\t\t\t\t2019041103310274500_b16-0740795","first-page":"84","article-title":"AACE\/ACE comprehensive type 2 diabetes management algorithm 2016","volume":"22","author":"American Association of Clinical Endocrinologists, Amercian College of Endocrinology","year":"2016","journal-title":"Endocr Pract"},{"key":"key\n\t\t\t\t2019041103310274500_b17-0740795","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1479164114542802","article-title":"The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system","volume":"11","author":"Schernthaner","year":"2014","journal-title":"Diab Vasc Dis Res"},{"key":"key\n\t\t\t\t2019041103310274500_b18-0740795","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MNH.0000000000000060","article-title":"Optimal targets for blood pressure control in chronic kidney disease","volume":"23","author":"Knight","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key\n\t\t\t\t2019041103310274500_b19-0740795","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD","volume":"62","author":"Taler","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b20-0740795","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041103310274500_b21-0740795","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upaday","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041103310274500_b22-0740795","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b23-0740795","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin\u2013angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041103310274500_b24-0740795","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103310274500_b25-0740795","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ki.2013.181","article-title":"LDL cholesterol in CKD\u2014to treat or not to treat?","volume":"84","author":"Massy","year":"2013","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103310274500_b26-0740795","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t2019041103310274500_b27-0740795","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041103310274500_b28-0740795","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041103310274500_b29-0740795","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baignent","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103310274500_b30-0740795","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019041103310274500_b31-0740795","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3949\/ccjm.73.3.289","article-title":"Anemia in chronic kidney disease: causes, diagnosis, treatment","volume":"73","author":"Nurko","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b32-0740795","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041103310274500_b33-0740795","first-page":"20","article-title":"The mechanism of erythropoietin action","volume":"18","author":"Koury","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b34-0740795","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3324\/haematol.2013.084624","article-title":"Manipulation of the hepcidin pathway for therapeutic purposes","volume":"98","author":"Fung","year":"2013","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t2019041103310274500_b35-0740795","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041103310274500_b36-0740795","first-page":"i6","article-title":"The future of intravenous iron in nephrology","volume":"4","author":"Coyne","year":"2011","journal-title":"NDT Plus"},{"key":"key\n\t\t\t\t2019041103310274500_b37-0740795","doi-asserted-by":"crossref","first-page":"f4822","DOI":"10.1136\/bmj.f4822","article-title":"Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials","volume":"347","author":"Litton","year":"2013","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041103310274500_b38-0740795","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b39-0740795","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/sdi.12168","article-title":"Iron and infection in hemodialysis patients","volume":"27","author":"Ishida","year":"2014","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t2019041103310274500_b40-0740795","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients","volume":"24","author":"Brookhart","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b41-0740795","volume-title":"Aranesp (darbepoetin alfa) package insert","year":"2016"},{"key":"key\n\t\t\t\t2019041103310274500_b42-0740795","volume-title":"Procrit (epoetin alfa) package insert","year":"2012"},{"key":"key\n\t\t\t\t2019041103310274500_b43-0740795","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b44-0740795","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2215\/CJN.05131107","article-title":"Anemia of chronic kidney disease","volume":"3","author":"Singh","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b45-0740795","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b46-0740795","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b47-0740795","unstructured":"Food and Drug Administration. Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (June2011). www.fda.gov\/Drugs\/DrugSafety\/ucm259639.htm (accessed 2015 Jul 16)."},{"key":"key\n\t\t\t\t2019041103310274500_b48-0740795","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000380972","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients","volume":"185","author":"Ogawa","year":"2015","journal-title":"Contrib Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b49-0740795","first-page":"210","article-title":"Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review","volume":"6","author":"Bolasco","year":"2009","journal-title":"Clinic Cases Miner Bone Metab"},{"key":"key\n\t\t\t\t2019041103310274500_b50-0740795","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.V441035","article-title":"Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure","volume":"4","author":"Vanholder","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b51-0740795","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b52-0740795","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2215\/CJN.04250510","article-title":"FGF-23 as a predictor of renal outcome in diabetic nephropathy","volume":"6","author":"Titan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b53-0740795","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041103310274500_b54-0740795","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00467-011-1822-0","article-title":"Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients","volume":"26","author":"Srivaths","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b55-0740795","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0272-6386(95)90541-3","article-title":"Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited","volume":"25","author":"Llach","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b56-0740795","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1681\/ASN.2008070692","article-title":"Vascular calcification: the killer of patients with chronic kidney disease","volume":"20","author":"Mizobuchi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b57-0740795","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ndt\/gfv055","article-title":"The challenge of controlling phosphorous in chronic kidney disease","volume":"31","author":"Cannata-Andia","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041103310274500_b58-0740795","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1525-139X.2010.00750.x","article-title":"Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies","volume":"23","author":"Gutierrez","year":"2010","journal-title":"Seminol Dial"},{"key":"key\n\t\t\t\t2019041103310274500_b59-0740795","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD)","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b60-0740795","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5414\/CN108209","article-title":"Oral phosphate binders in CKD\u2014is calcium the (only) answer?","volume":"81","author":"Goldsmith","year":"2014","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b61-0740795","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJNRD.S78040","article-title":"Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide","volume":"9","author":"Cernaro","year":"2016","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b62-0740795","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b63-0740795","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2369-12-20","article-title":"Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?","volume":"12","author":"Mudge","year":"2011","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b64-0740795","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000111061","article-title":"Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients","volume":"28","author":"Shantouf","year":"2008","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b65-0740795","unstructured":"European Medicines Agency. Assessment report: Velphoro (2014). www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002705\/human_med_001795.jsp&mid=WC0b01ac058001d124 (accessed 2016 Jul 15)."},{"key":"key\n\t\t\t\t2019041103310274500_b66-0740795","volume-title":"Velphoro (sucroferric oxyhydroxide) package insert","year":"2014"},{"key":"key\n\t\t\t\t2019041103310274500_b67-0740795","first-page":"329","article-title":"Ferric citrate (Auryxia) for the treatment of hyperphosphatemia","volume":"40","author":"Pennoyer","year":"2015","journal-title":"P T"},{"key":"key\n\t\t\t\t2019041103310274500_b68-0740795","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103310274500_b69-0740795","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041103310274500_b70-0740795","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/ki.2009.288","article-title":"Chronic kidney disease, hypovitaminosis D, and mortality in the United States","volume":"76","author":"Mehrotra","year":"2009","journal-title":"Kidney Int"},{"issue":"suppl 5","key":"key\n\t\t\t\t2019041103310274500_b71-0740795","first-page":"S5","article-title":"Vitamin D and chronic kidney disease","volume":"19","author":"Williams","year":"2009","journal-title":"Ethn Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b72-0740795","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.ajkd.2014.05.018","article-title":"25-hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report","volume":"64","author":"Kramer","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103310274500_b73-0740795","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(76)91140-5","article-title":"Vitamin-D deficiency in the osteomalacia of chronic renal failure","volume":"2","author":"Eastwood","year":"1976","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103310274500_b74-0740795","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103310274500_b75-0740795","volume-title":"Senispar (cinacalcet) package insert","year":"2004"},{"key":"key\n\t\t\t\t2019041103310274500_b76-0740795","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103310274500_b77-0740795","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"Plos Med"},{"key":"key\n\t\t\t\t2019041103310274500_b78-0740795","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103310274500_b79-0740795","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized trial to evaluate the effects of cinacalcet plus low dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/11\/795\/28336110\/ajhp0795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T21:33:51Z","timestamp":1659044031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/11\/795\/5102549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160559","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,1]]},"published":{"date-parts":[[2017,6,1]]}}}